Hemostasis parameters in patients after coronary artery bypass surgery for stable angina

The objective of research is to assess the significance of hemostatic profile in the postoperative period after coronary artery bypass surgery for predicting the one-year functioning of the grafts.

Materials and methods. 46 men, who had coronary artery bypass surgery (CABS) for stable angina, were examined. 23 of them had 2 type diabetes mellitus (DM2), 23 of them did not have diabetes mellitus. All patients underwent fibrinogen, soluble fibrin monomer complex, D-dimer, induced platelet aggregation and lupus anticoagulant blood tests on the 14th day after surgery. The patients had coronary and bypass graft angiography for the assessment of graft patency a year after surgery.

Results. During the postoperative period, there were no statistically significant differences between patients with DM2 and patients without DM2 in the results of the above hemostatic profile tests (p value for the Mann-Whitney test is >0.05). Lupus anticoagulant was detected in 9 patients with DM2 and in 12 patients without DM2 (p value for Fisher’s exact test is 0.554). 10 patients with DM2 and 6 patients without DM2 had graft occlusions a year after surgery; the differences for this sign were not statistically significant (p value for Fisher’s exact test is 0.18). Fibrinogen, soluble fibrin-monomer complex, D-dimer, and induced platelet aggregation tests did not demonstrate prognostic significance in relation to graft occlusions in both groups of patients (p for χ² in the logistic regression model is >0.05). The factors associated with higher risk of graft occlusion in patients with DM2 were high ratio between screening and confirmatory test for the detection of lupus anticoagulant (odds ratio 2.27; 95% -confidence interval 1.119-1.238; p <0.05).

Conclusion. After coronary bypass surgery, the one-year risk of graft thrombosis is higher in patients with DM2 and high positive LA activity.

1. Bogachev-Prokophiev AV, Sapegin AV, Karaskov AM. Cardiac surgery in Siberia: present and perspectives. Patologiya krovoobrashcheniya i kardiokhirurgiya. 2017; 21 (4):13-18. [in Russian]

2. Janiec M., Nazari Shafti T.Z., Dimberg A. et al. Graft failure and recurrence of symptoms after coronary artery bypass grafting. Scand Cardiovasc J. 2018; 52(3):113-119. doi: 10.1080/14017431.2018.1442930

3. Gaudino M., Antoniades C., Benedetto U. et al. Mechanisms, Consequences, and Prevention of Coronary Graft Failure. Circulation. 2017 Oct 31; 136(18):1749-1764. doi: 10.1161/GRCULATIONAHA.117.027597

4. Kogan A., Ram E., Levin S. Impact of type 2 diabetes mellitus on short- and long-term mortality after coronary artery bypas surgery. Cardiovasc Diabetol. 2018; 17(1):151-159. doi: 10.1186/s12933-018-0796-7

5. Wang Z., Qian Z., Ren J. et al. Long Period and High Level of D-Dimer after Coronary Artery Bypass Grafting Surgery. Int Heart J. 2018; 59(1):51-57. doi: 10.1536/ihj.16-595

6. Yanagawa B., Algarni K.D., Singh S.K., et al. Clinical, biochemical, and genetic predictors of coronary artery bypass graft failure. J Thorac Cardiovasc Surg. 2014; 148(2):515-520. doi: 10.1016/j.jtcvs.2013.10.011

7. Montalescot G., Sechtem U., Achenbach S., et al. 2013 ESC guidelines on the management of stable coronary artery disease. The Task force on the management of stable coronary artery disease of the European Society of Cardiology. European Heart Journal. 2013; 34(38):2949-3003. doi: 10.1093/eurheartj/eht296

8. Petrik G.G., Pavlischuk S.A., Kosmacheva E.D. Diabetes mellitus and cardiovascular disorders: focus on hemostasis. Russ J Cardiol. 2014;3(107): 114-118. [in Russian]

9. Stroyev Yu.I., Utekhin V.I., Faitelson V.I., et al. Platelet link of hemostasis in diabetes mellitus. Clinical pathophysiology. 2015; 4: 41-49. [in Russian]

10. Sobel B.E., Hardison R.M., Genuth S. et al. Profibrinolytic, antithrombotic, and antiinflammatory effects of an insulin-sensitizing strategy in patients in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Circulation. 2011; 124(6):695-703. doi: 10.1161/CIRCULATIONAHA.110.014860.

11. Zacho M., Rafiq S, Kelb$k H et al. Hypercoagulability in relation to coronary artery bypass graft patency and clinical outcome. Scand Cardiovasc J. 2013; 47(2):104-8. doi: 10.3109/14017431.2012.754934

12. Diou M., You N., Gaye ND, et al. Comparative Study Of Coronary Artery Disease In Diabetics And Non-Diabetics In The Department Of Cardiology Of Aristide Le Dantec University Hospital. Mali Med. 2017; 32(3):40-43.

13. Morton K.E., Gavoghan T.P., Krilis S.A. et al. Coronary artery bypass graft failure — an autoimmune phenomen? Lancet. 1986; 11:1353-1357.

14. Pengo V., Biasiolo A., Gresele P,, et al. A Comparison of Lupus Anticoagulant-Positive Patients with Clinical Picture of Antiphospholipid Syndrome and Those Without. Arteriosclerosis, Thrombosis, and Vascular Biology. 2007;27:e309-e310.

15. Warltier D.C., Laffey J.G., Boylan J.F. et al. The Systemic Inflammatory Response to Cardiac Surgery: Implications for the Anesthesiologist. Anesthesiology. 2002; 97:215-252.